Atyr Pharma (ATYR) revenue and earnings history
Atyr Pharma reported revenue of $190K for fiscal 2025 (year ended Dec 31, 2025), −19.1% on the year before, and net income of −$74.1M.
Over 6 years, from fiscal 2019 to fiscal 2025, revenue grew at a compound rate of −12.5% a year.
Revenue and net income, 13 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $190K−19.1% | −$77.6M | −$74.1M | −$62M | $77K | −$62.1M | $5M | — | — | $10.7M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Atyr Pharma (ATYR) on OQRO.
Common questions
What was Atyr Pharma's revenue in fiscal 2025?
$190K for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 5, 2026. That is −19.1% on fiscal 2024 ($235K).
How fast has Atyr Pharma's revenue grown?
From $422K in fiscal 2019 to $190K in fiscal 2025: a compound annual growth rate of −12.5% over 6 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Atyr Pharma been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Atyr Pharma tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
